AIM ImmunoTech (AIM) Stock Jumps 97% After Japan Patent Approval for Cancer Treatment

TLDR

• AIM ImmunoTech stock surged 97.18% on Wednesday after Japan approved its cancer treatment patent
• The patent covers using Ampligen with checkpoint inhibitors across multiple cancer types, including pancreatic cancer
• The patent is valid until December 20, 2039
• AIM already holds similar patents in the U.S. and the Netherlands
• The company plans to seek orphan drug designation in Japan for Ampligen in pancreatic cancer treatment

AIM ImmunoTech (AIM) stock nearly doubled on Wednesday after the Japanese Patent Office approved a patent for its cancer treatment method combining Ampligen with checkpoint inhibitors.

The stock was up 97.18% on the day, adding to a 24.11% gain year-to-date. Despite the rally, AIM is still down 94.21% over the past 12 months.

AIM ImmunoTech Inc., AIM

Trading volume spiked alongside the move. Around 10.6 million units changed hands on Wednesday, compared to a three-month daily average of about 2.7 million.

The patent, originally granted in September 2025, cleared a six-month opposition window before becoming final. It covers a broad range of cancer types, with a particular focus on pancreatic cancer.

Both the U.S. and Japan are expected to see a rise in pancreatic cancer cases by 2030. AIM described the disease as “an extremely lethal and unmet global health problem.”

The Japanese patent runs until December 20, 2039, giving AIM a long window to develop and potentially commercialize its approach in that market.

AIM’s Existing Patent Portfolio

AIM already holds a U.S. patent for using Ampligen with an anti-PD-L1 antibody, and a Dutch patent for combining Ampligen with checkpoint blockade drugs — including Keytruda, Opdivo, and Imfinzi.

The Japan approval adds a third major market to that portfolio, and the company says it intends to continue expanding its IP position there.

The company is also pursuing orphan drug designation in Japan for Ampligen in pancreatic cancer treatment, which would further extend its IP footprint.

Financial Picture Remains Challenging

Despite the patent news, AIM’s financials carry serious warning signs. The company has a market cap of around $3 million and revenue of just $0.11 million.

Its operating margin sits at -13,006%, and its net margin is -14,062%. The current ratio is 0.64, which flags liquidity concerns.

The Altman Z-Score stands at -120.53, placing AIM firmly in the financial distress zone. The Beneish M-Score of 1.8 also raises questions about financial reporting.

Institutional ownership is low at 3.31%. Insider ownership sits at 13.41%.

AIM has a beta of 2.16, meaning it tends to move much more sharply than the broader market. Wednesday’s session made that clear.

The RSI of 38.02 had been pointing toward oversold territory before the patent news triggered the spike.

AIM’s Ampligen remains unapproved in most global markets, though it is approved for severe Chronic Fatigue Syndrome in Argentina.

The patent opposition period in Japan officially ended, clearing the way for the company to move forward with commercialization plans in the region.

The post AIM ImmunoTech (AIM) Stock Jumps 97% After Japan Patent Approval for Cancer Treatment appeared first on CoinCentral.